EGFR G796D mutation mediates resistance to osimertinib

Osimertinib is an effective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in multiple countries and regions for patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). Despite impressive initial tumor responses, development o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Zheng, Di, Hu, Min, Bai, Yu, Zhu, Xuehua, Lu, Xuesong, Wu, Chunyan, Wang, Jiying, Liu, Li, Wang, Zheng, Ni, Jian, Yang, Zhenfan, Xu, Jianfang
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564797/
https://ncbi.nlm.nih.gov/pubmed/28572531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17913
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados